Abstract
To the Editor: Limited studies are available on the long-term efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis (AD) beyond the 52-week follow-up. A recent publication by our group showed favorable efficacy outcomes with no new safety signals in patients with AD over 52-weeks of dupilumab treatment.1 An observational prospective cohort study of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry showed consistent safety and efficacy outcomes up to week 84.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
